Development of Drug Loaded Nanoparticles for Treatment of Mycobacterium avium Infection

Currently, about one third of the world's population is latently infected with Mycobacterium tuberculosis and about 4 million people die from the disease annually worldwide. Although treatment with antimicrobials can be curative, many people fail to complete the prescribed therapeutic regimen w...

Full description

Bibliographic Details
Main Author: Restis, Eva Marie
Other Authors: Veterinary Medicine
Format: Others
Published: Virginia Tech 2015
Subjects:
Online Access:http://hdl.handle.net/10919/52565
id ndltd-VTETD-oai-vtechworks.lib.vt.edu-10919-52565
record_format oai_dc
spelling ndltd-VTETD-oai-vtechworks.lib.vt.edu-10919-525652020-09-29T05:35:18Z Development of Drug Loaded Nanoparticles for Treatment of Mycobacterium avium Infection Restis, Eva Marie Veterinary Medicine Sriranganathan, Nammalwar Riffle, Judy S. Falkinham, Joseph O. III Subbiah, Elankumaran tuberculosis nanoparticle Mycobacterium avium Currently, about one third of the world's population is latently infected with Mycobacterium tuberculosis and about 4 million people die from the disease annually worldwide. Although treatment with antimicrobials can be curative, many people fail to complete the prescribed therapeutic regimen which can increase the risk of disease re-emergence, spread of infection to others and development of drug resistance. An improved approach is urgently needed for patient compliance. Development of safe and effective colloidal drug delivery systems may reduce the amount and frequency of antimicrobial therapy needed. The major goal of this research effort is to explore the safety and efficacy of antimicrobial loaded nanoparticles against M. avium. Various in vitro efficacy studies were done with a) amikacin-loaded nanoparticles, b) clarithromycin-loaded nanoparticles, and c) with aerogel nanoparticles loaded with rifampicin, clarithromycin and ethambutol. Clarithromycin (CLA) and amikacin (AMK) loaded nanoparticles showed a significant reduction in viable M. avium compared to free antibiotics and untreated controls. Cytotoxicity assays revealed that all types of drug-laden nanoparticles were non-toxic to J774A.1 mouse macrophage cells at therapeutic doses. In vivo efficacy studies showed that only amikacin-loaded polymeric nanoparticles improved clearance compared to free amikacin in M. avium infected BALB/c mice. In general, none of the nanoparticle formulations elicited any significant microscopic lesions in the organs of infected mice at tested doses. Each nanoparticle formulation was analyzed physicochemically for size, zeta potential, amount of drug load, minimum inhibitory concentration (MIC) and stability. Both the AMK and CLA polymeric nanoparticles were below 200 nm in size and had a slightly negative overall surface charge, aerogel nanoparticles were somewhat larger in size. The amount of drug load varied between all three nanoparticles and is largely dependent on the chemical structure and interactions between the nanoparticle and drug. The AMK and CLA nanoparticles were relatively stable under varying environmental conditions and time points and had MIC ranges equivalent to the respective free drugs. Ph. D. 2015-05-23T08:05:01Z 2015-05-23T08:05:01Z 2014-10-03 Dissertation vt_gsexam:1738 http://hdl.handle.net/10919/52565 In Copyright http://rightsstatements.org/vocab/InC/1.0/ ETD application/pdf Virginia Tech
collection NDLTD
format Others
sources NDLTD
topic tuberculosis
nanoparticle
Mycobacterium avium
spellingShingle tuberculosis
nanoparticle
Mycobacterium avium
Restis, Eva Marie
Development of Drug Loaded Nanoparticles for Treatment of Mycobacterium avium Infection
description Currently, about one third of the world's population is latently infected with Mycobacterium tuberculosis and about 4 million people die from the disease annually worldwide. Although treatment with antimicrobials can be curative, many people fail to complete the prescribed therapeutic regimen which can increase the risk of disease re-emergence, spread of infection to others and development of drug resistance. An improved approach is urgently needed for patient compliance. Development of safe and effective colloidal drug delivery systems may reduce the amount and frequency of antimicrobial therapy needed. The major goal of this research effort is to explore the safety and efficacy of antimicrobial loaded nanoparticles against M. avium. Various in vitro efficacy studies were done with a) amikacin-loaded nanoparticles, b) clarithromycin-loaded nanoparticles, and c) with aerogel nanoparticles loaded with rifampicin, clarithromycin and ethambutol. Clarithromycin (CLA) and amikacin (AMK) loaded nanoparticles showed a significant reduction in viable M. avium compared to free antibiotics and untreated controls. Cytotoxicity assays revealed that all types of drug-laden nanoparticles were non-toxic to J774A.1 mouse macrophage cells at therapeutic doses. In vivo efficacy studies showed that only amikacin-loaded polymeric nanoparticles improved clearance compared to free amikacin in M. avium infected BALB/c mice. In general, none of the nanoparticle formulations elicited any significant microscopic lesions in the organs of infected mice at tested doses. Each nanoparticle formulation was analyzed physicochemically for size, zeta potential, amount of drug load, minimum inhibitory concentration (MIC) and stability. Both the AMK and CLA polymeric nanoparticles were below 200 nm in size and had a slightly negative overall surface charge, aerogel nanoparticles were somewhat larger in size. The amount of drug load varied between all three nanoparticles and is largely dependent on the chemical structure and interactions between the nanoparticle and drug. The AMK and CLA nanoparticles were relatively stable under varying environmental conditions and time points and had MIC ranges equivalent to the respective free drugs. === Ph. D.
author2 Veterinary Medicine
author_facet Veterinary Medicine
Restis, Eva Marie
author Restis, Eva Marie
author_sort Restis, Eva Marie
title Development of Drug Loaded Nanoparticles for Treatment of Mycobacterium avium Infection
title_short Development of Drug Loaded Nanoparticles for Treatment of Mycobacterium avium Infection
title_full Development of Drug Loaded Nanoparticles for Treatment of Mycobacterium avium Infection
title_fullStr Development of Drug Loaded Nanoparticles for Treatment of Mycobacterium avium Infection
title_full_unstemmed Development of Drug Loaded Nanoparticles for Treatment of Mycobacterium avium Infection
title_sort development of drug loaded nanoparticles for treatment of mycobacterium avium infection
publisher Virginia Tech
publishDate 2015
url http://hdl.handle.net/10919/52565
work_keys_str_mv AT restisevamarie developmentofdrugloadednanoparticlesfortreatmentofmycobacteriumaviuminfection
_version_ 1719343781824692224